Regulatory delays shortfall in capacity stall new drugs
Article Abstract:
The article discusses how the shortfall in manufacturing capacity and an increasingly strict U.S. drug regulator are delaying biotechnology's first wave of pharmaceuticals. This is causing some biotech companies to go back to the market to raise money, which is threatening stock valuations.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
AstraZeneca's Crestor likely to get U.S. nod
Article Abstract:
AstraZeneca PLC's Crestor anti-cholesterol drug is expected to be approved in the U.S. However, analysts are split on whether the drug will be approved in higher doses.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Glaxo drug's new version gets 'approvable letter' from U.S
Article Abstract:
GlaxoSmithKline PLC's Wellbutrin XL drug has received an approvable letter in the US. Wellbutrin XL is a newer version of the company's Wellbutrin antidepressant.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: More declines in chip sales. Intel offers chip set earlier
- Abstracts: Sun says earnings could trail Wall Street forecasts by 67%. Sun Micro loss will be wider than expected. Dell blames price cuts in latest profit warning
- Abstracts: Eye surgery ads go for mass appeal. Granny bares her teeth. Open road drives new brand image
- Abstracts: Security woes don't slow Reed's push into data collection. Vodafone to put 'Push E-Mail' in cell phones across Europe
- Abstracts: Lawsuits may stall penny-stock move by Deutsche Boerse. Flextronics swings to net loss